Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor (Monitor-GCSF)

Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for febrile neutropenia.

Inclusion Criteria:

• Male or female adults (age > / = 18 years)
• Diagnosed with one of the following types and stages of tumors: stage III or IV breast cancer; stage III or IV ovarian cancer; stage III or IV bladder cancer; stage III or IV lung cancer; metastatic prostate cancer; stage III or IV diffuse large B-cell lymphoma; multiple myeloma.
• Planned to receive primary prophylaxis with ZARZIO® at the first cycle of chemotherapy (regardless of line of chemotherapy); or receiving secondary prophylaxis with ZARZIO® irrespective of chemotherapy cycle.
• Treated with commercially available ZARZIO® per physician's best clinical judgment and per current European ZARZIO® label.
• Female patients must be either post-menopausal for one year or surgically sterile or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device. Oral contraceptive use is allowed.
• Informed written consent to participate in the study by patients or their legal guardian.

Exclusion Criteria:

• Patients with myeloid malignancies, with the exception of multiple myeloma.
• Sensitivity to ZARZIO® or any other CSF.
• Hypersensitivity to E. coli-derived proteins.
• Radiotherapy to ≥ 20% of total body bone.
• Infection within two weeks of starting current line of chemotherapy.
• Patients with several medical condition(s) that in view of the investigator prohibits participation in the study.
• Patients with willfully negligent nonadherence to their cancer treatment.
• Use of any investigational agent in the 30 days prior to enrollment.
• Women of childbearing potential not using the contraception method(s) described above.
• Women who are breastfeeding.